和黄医药（HCM）今日盘前大涨5.95%，主要受到公司2024年财报及多项利好消息的推动。
财报显示，和黄医药2024年实现净收益3770万美元，扭亏为盈，远超市场预期的亏损2140万美元。公司肿瘤产品表现亮眼，市场销售额同比大增134%至5.01亿美元，其中海外市场贡献显著，FRUZAQLA®在美国等市场的销售额达2.91亿美元。尽管整体收入有所下降，但肿瘤产品的综合收入增长65%至2.71亿美元，超出预期。
此外，和黄医药还发布了多项积极消息。公司与信达生物合作开发的呋喹替尼联合信迪利单抗用于治疗晚期肾细胞癌的II/III期临床试验达到主要终点，为未来新适应症的开发奠定基础。同时，公司宣布以6.08亿美元出售合资企业上海和黄药业的部分股权，这一战略举措有望优化公司资源配置，进一步聚焦创新药业务。这些利好因素共同推动了投资者信心，带动股价大幅上涨。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.